Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma

• Status: Completed
• Trial end date: 2015-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial compares and contrasts lymph node mapping using indocyanine green (IC-GREEN), isosulfan blue (ISB), and TSC and Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC).

Study participants with malignant melanoma will undergo all 3 evaluations to assess the extent of the spread of the melanoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Ability to understand and willingness to sign informed consent document

• Signed written informed consent

• Malignant melanoma (MM) undergoing sentinel lymph node biopsy (SNLB)

• 18 years of age or older

• Complete blood count (CBC) and metabolic panel within 6 months

Exclusion Criteria:

• History of hepatic or renal failure

• Allergy to iodine containing products

• Pregnant or may be pregnant

• Psychiatric or addictive disorders that in the opinion of the research team, may not be able to meet study requirements

• Undergoing dialysis